India’s decision comes as its domestic vaccination campaign has picked up after a slow start. The government says it expects to finish inoculating all 944 million adults in the country by December.
So far, 61 percent of adults in India have received their first dose, according to government data. The two main vaccines in use are Covishield, the local name for the AstraZeneca vaccine, manufactured in India by the Serum Institute of India, and Covaxin, produced by the Indian company Bharat Biotech.
The decision on exports comes days before India’s Prime Minister Narendra Modi arrives in the United States, where he is scheduled to participate in a summit including President Biden and the leaders of Australia and Japan, and to speak at the annual gathering of the U.N. General Assembly. The global vaccination effort is expected to be a focus of both meetings, and the Biden administration had been trying to persuade Mr. Modi to resume exports.
India was initially expected to be the main vaccine supplier for the Covax initiative, and its export ban came as a heavy blow to the program, which is so far behind schedule that fewer than 10 percent of people in poor countries are vaccinated.
India began to expand vaccine coverage to all adults in the country in May, after a devastating second wave of infections that overburdened its health care infrastructure, leaving thousands dead and many struggling to find hospital beds. The country’s total caseload stood on Monday about 318,000, the lowest in approximately six months, according to official data.